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Abstract: (1) In vitro, bone marrow-derived stromal cells (BMSCs) demonstrate inter-donor
phenotypic variability, which presents challenges for the development of regenerative therapies.
Here, we investigated whether the frequency of putative BMSC sub-populations within the freshly
isolated mononuclear cell fraction of bone marrow is phenotypically predictive for the in vitro derived
stromal cell culture. (2) Vertebral body, iliac crest, and femoral head bone marrow were acquired
from 33 patients (10 female and 23 male, age range 14–91). BMSC sub-populations were identified
within freshly isolated mononuclear cell fractions based on cell-surface marker profiles. Stromal cells
were expanded in monolayer on tissue culture plastic. Phenotypic assessment of in vitro derived cell
cultures was performed by examining growth kinetics, chondrogenic, osteogenic, and adipogenic
differentiation. (3) Gender, donor age, and anatomical site were neither predictive for the total yield
nor the population doubling time of in vitro derived BMSC cultures. The abundance of freshly
isolated progenitor sub-populations (CD45−CD34−CD73+, CD45−CD34−CD146+, NG2+CD146+)
was not phenotypically predictive of derived stromal cell cultures in terms of growth kinetics nor
plasticity. BMSCs derived from iliac crest and vertebral body bone marrow were more responsive to
chondrogenic induction, forming superior cartilaginous tissue in vitro, compared to those isolated
from femoral head. (4) The identification of discrete progenitor populations in bone marrow by
current cell-surface marker profiling is not predictive for subsequently derived in vitro BMSC cultures.
Overall, the iliac crest and the vertebral body offer a more reliable tissue source of stromal progenitor
cells for cartilage repair strategies compared to femoral head.
Keywords: bone marrow stromal cells; MSC; pericytes; femoral head; vertebral body; iliac crest;
chondrogenesis
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1. Introduction
Adult bone marrow contains a heterogeneous population of stromal cells, bone marrow-derived
stromal cells (BMSCs) (also referred to as mesenchymal stromal cells (MSCs) or skeletal progenitor cells),
which may be isolated in vitro and differentiated toward chondrogenic, osteogenic, and adipogenic
cell lineages [1–4]. Recent lineage tracing and fate mapping studies suggest that, apart from being
phenotypically heterogeneous, these bone marrow stromal cells are also developmentally distinct.
Evidence points not only to the somatic lateral plate mesoderm [5,6] but also to neural crest origins [7].
In vitro selected and culture expanded BMSCs have historically been characterized by their
adherence to tissue culture plastic, multipotent differentiation potential, and cluster of differentiation
(CD) marker profile: ≥95% CD90+, CD73+, CD105+ and ≥95% CD45−, CD34−, CD14/CD11b,
CD79α/CD19−, HLA−DR− [8]. Despite this commonly shared set of criteria, genotypic and phenotypic
variation between BMSC cultures is very prominent. Inter- and intra-donor variations are widely
reported and present challenges not only for biological investigations but also as we strive to develop
efficacious cell-based therapies.
Studies characterizing the colony forming unit (CFU) fraction from freshly isolated mononuclear
cells (MNCs) reveal that the classical BMSC cell surface marker profile is in fact largely acquired
during monolayer culture [9–12]. It is now clear that freshly isolated BMSC populations exhibit a
more diverse cell surface marker expression profile than previously realized. Indeed, BMSCs are an
inherently heterogeneous population of cells occupying spatially and functionally discrete endosteal,
stromal, and perivascular niches [13–15]. Rasini et al., 2013 reported site-specific phenotypes based
on cell-surface marker expression between cells in different anatomical localizations [16]. Previous
studies focused on characterizing individual BMSC populations in human bone marrow within the
freshly isolated MNC fraction: CD45low/D7FIB+/CD271+ [11]; lin−/CD271+/CD45−/CD146+ [17];
CD64bright/CD31bright/CD14neg [18]; CD13high/CD105+/CD45− [19]; CD145−/CD34−/CD146+ [20–22];
PDPN+/CD146−CD73+CD164+ [23]. Whether the abundance of these discrete BMSC subsets may
determine the yield and/or the phenotypic characteristics of the subsequently in vitro derived stromal
population remains unclear.
Several groups have investigated the influence of donor demographics, particularly donor age, on the
phenotypic variation observed in BMSC cultures with inconsistent results. Whilst some studies suggest a
decrease in CFU formation efficiency with age [24,25], others suggest that progenitor cell numbers are
maintained [26,27]. With regards to proliferation capacity, it was reported that there is a significant decline
in maximal population doublings achieved in cultures from older donors [27,28], and accordingly that
population doubling time increases [26] with age. Conversely, others report no age-related differences in
maximal population doublings [29] or population doubling time [30]. Contradictory results in terms of
plasticity are apparent, with some groups reporting that the ability of BMSCs to differentiate osteogenically,
adipogenically, and chondrogenically in vitro is not influenced by donor age [26,30,31]. In contrast,
an age-related decline in MSC chondrogenesis from male donors was reported [32].
BMSCs may be isolated from several bone marrow sources—vertebral body [33], iliac crest [34],
and the femoral head [35]. Although BMSC phenotype has been described in the case of these respective
tissue sources, differences in isolation and culture protocols between research groups (which is known
to cause phenotypic shift) prevents reliable comparison [36]. Previous groups have compared stromal
cells derived from vertebral body vs. iliac crest [34,37]. As far as we are aware, there are no reports of a
single study directly comparing derived BMSC populations from vertebral body, iliac crest, and femoral
head. We hypothesized that the abundance of progenitor cell populations from these tissues and the
behavior of derived BMSC cultures may be different. The aim of this study was to ascertain whether
the abundance of specific BMSC subpopulations present in the initial MNC fraction is predictive
of the yield and the phenotype of in vitro derived BMSC cultures. In addition to this, we directly
compared cell populations from different bone marrow tissue sources and investigated the effect of
donor demographics. MNCs were characterized by applying previously reported cell surface marker
panels identifying BMSC populations; CD45−CD34−CD73+ [38], CD45−CD34−CD146+ [20–22] and
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pericytes CD146+NG2+ [39]. The yield, the growth kinetics, and the multipotency of derived BMSC
cultures were compared between different tissue sources and correlated to the relative abundance of
freshly isolated progenitor cells.
2. Results
2.1. BMSC Yield and Growth Kinetics
In total, we analyzed BMSCs from 33 donors, whereof 15 cultures were isolated from femoral
head-derived bone marrow, eight from iliac crest, and 10 from vertebral body (Table 1). All BMSCs
exhibited a typical fibroblastic morphology when cultured on tissue culture plastic. We assessed cell
yield upon first passaging in relation to the number of originally seeded mononuclear cells. There
was no correlation between BMSC yield at first passage and donor age (Figure 1A). No significant
differences were observed when comparing different anatomical sites or between male and female
donors (Figure 1C). Following subsequent culture expansion, variation in growth kinetics between
donors was apparent and was characteristic of primary human BMSCs. No correlation was seen
between donor age and the number of population doublings/day in BMSC cultures between p0–p1
(Figure 1B). Furthermore, there were no significant differences in the mean number of population
doublings/day between BMSC cultures when comparing the three tissue sources of bone marrow or
male and female donors (Figure 1D).
Table 1. Demographical information from patients where bone marrow samples were acquired.
The total yield of mononuclear cells (MNCs) isolated by density centrifugation is shown. Bone
marrow-derived stromal cells (BMSC) yield at p0/MNC originally seeded and the population doubling
time (p0–p1) of tissue-culture plastic selected and monolayer expanded stromal cell populations.
Donor Age Sex Tissue Source MNCsSeeded
MSC Yield at
p0/MNCs Seeded
MSC PDT
(p0–p1)
1 86 Female Femoral head 1.97 × 106 0.30 0.69
2 67 Female Femoral head 1.91 × 107 0.19 0.77
3 86 Female Femoral head 2.33 × 107 0.39 0.77
4 51 Male Femoral head 6.25 × 106 0.58 1.00
5 91 Male Femoral head 4.00 × 105 0.51 0.91
6 67 Male Femoral head 3.44 × 106 0.06 0.73
7 46 Male Femoral head 5.05 × 106 0.95 0.94
8 83 Male Femoral head 6.70 × 106 0.13 0.35
9 81 Male Femoral head 2.53 × 106 0.38 0.65
10 83 Male Femoral head 1.53 × 107 0.12 0.70
11 75 Female Femoral head 3.75 × 106 0.95 0.55
12 61 Male Femoral head 1.13 × 107 0.46 0.57
13 68 Male Femoral head 4.21 × 106 0.24 0.85
14 83 Male Femoral head 6.33 × 106 0.14 0.80
15 82 Male Femoral head 5.10 x 107 0.14 0.24
16 88 Female Iliac crest 4.35 × 107 0.12 0.59
17 48 Female Iliac crest 4.80 × 107 0.25 0.86
18 46 Male Iliac crest 3.20 × 107 0.17 0.55
19 14 Male Iliac crest 5.25 × 107 0.16 0.61
20 41 Male Iliac crest 7.84 ×106 0.34 0.44
21 32 Male Iliac crest 8.04 × 107 0.39 0.73
22 23 Female Iliac crest 1.43 × 107 0.22 0.95
23 53 Male Iliac crest 6.40 × 107 0.09 0.57
24 75 Female Vertebral body 6.40 × 107 0.10 1.00
25 64 Female Vertebral body 2.77 × 107 0.73 0.65
26 39 Male Vertebral body 1.60 × 107 0.26 0.71
27 67 Male Vertebral body 1.60 × 107 0.12 0.44
28 46 Male Vertebral body 3.20 × 107 0.33 0.85
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Table 1. Cont.
Donor Age Sex Tissue Source MNCsSeeded
MSC Yield at
p0/MNCs Seeded
MSC PDT
(p0–p1)
29 89 Male Vertebral body 3.20 × 107 0.14 0.70
30 77 Male Vertebral body 1.60 × 107 0.75 0.16
31 40 Male Vertebral body 8.00 ×106 0.32 0.78
32 60 Male Vertebral body 3.20 × 107 0.66 0.21
33 75 Female Vertebral body 3.20 × 107 0.13 0.52
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Figure 1. Growth kinetics of BMSCs from different bone marrow sources. (A,C) The number of cells 
obtained at p0 in relation to originally seeded MNCs (yield/seeded) was recorded as a measure of 
initial frequency of MSCs. (B,D) The population doubling time (PDT) between p0 and p1 is shown as 
the measure of the proliferation capacity of MSCs. (A,B) Donor age (correlation tested with Spearman 
rank test, individually calculated for each tissue source and for the complete data set (linear regression 
depicted as dashed line; yield: r = −0.17, p < 0.34; PDT: r = −0.23, p = 0.15)), (C,D) bone marrow source 
(fh: femoral head, ic: iliac crest, vb: vertebral body) and gender did not affect MSC yield or PDT. 
Kruskal–Wallis statistics with Dunn’s multiple comparison test was performed to test for differences 
in yield/seeded and PDT, respectively, between different tissue sources. n = 33. 
2.2. Identification of Putative Progenitor Cell Subsets within the Freshly Isolated MNC Fraction 
Identification of freshly isolated BMSCs in the MNC fraction is challenging due to low 
abundance and the lack of specific cell surface markers. Here, we applied three different marker 
panels to detect putative BMSC populations (Figure 2). We applied an established marker panel for 
perivascular progenitor cells, CD45−CD34−CD146+ [20], in addition to a dual stain for pericyte cell 
surface markers, CD146 and NG2 [39]. Finally, in accordance with published literature and our own, 
we identified the CD45−CD34−CD73+ MSC subset, which is reported at perivascular, endosteal, and 
stromal sites [11,12,16,38]. As expected, BMSCs identified by putative cell-surface marker panels were 
present at very low abundance within the MNC fraction across all tissue sources (Figure 2A–D: 
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(fh: femoral head, ic: liac crest, vb: vertebral body) and gender did not affect MSC yield or PDT.
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2.2. Identification of Putative Progenitor Cell Subsets within the Freshly Isolated MNC Fraction
Identification of freshly isolated BMSCs in the MNC fraction is challenging due to low abundance
and the lack of specific cell surface markers. Here, we applied three different marker panels to detect
putative BMSC populations (Figure 2). We applied an established marker panel for perivascular
progenitor cells, CD45−CD34−CD146+ [20], in addition to a dual stain for pericyte cell surface
markers, CD146 and NG2 [39]. Finally, in accordance with published literature and our own,
we identified the CD45−CD34−CD73+ MSC subset, which is reported at perivascular, endosteal, and
stromal sites [11,12,16,38]. As expected, BMSCs identified by putative cell-surface marker panels
were present at very low abundance within the MNC fraction across all tissue sources (Figure 2A–D:
CD45−CD34−CD146+: 0.61± 0.62%, CD45−CD34−CD73+: 0.48± 0.54%, CD146+NG2+: 3.85% ± 3.98).
The relative abundances of the above BMSC populations were plotted against each other in order to
examine marker panel correspondence (Figure 2E–G). The abundances of CD45-CD34-CD146+ and
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CD45−CD34−CD73+ populations correlated, although this was not statistically significant (Figure 2G).
In contrast, dual staining for CD146 and NG2 detected a larger proportion of MNCs (Figure 2C:
3.85 ± 3.98%), which did not correlate with either CD45−CD34−CD146+/CD45−CD34−CD73+ subsets
(Figure 2E,F).
Int. J. Mol. Sci. 2019, 20, x 5 of 22 
CD45−CD34−CD146+: 0.61 ± 0.62%, CD45−CD34−CD73+: 0.48 ± 0.54%, CD146+NG2+: 3.85% ± 3.98). 
The relative abundances of the above BMSC populations were plotted against each other in order to 
examine marker panel correspondence (Figure 2E–G). The abundances of CD45-CD34-CD146+ and 
CD45−CD34−CD73+ populations correlated, although this was not statistically significant (Figure 
2G). In contrast, dual staining for CD146 and NG2 detected a larger proportion of MNCs (Figure 2C: 
3.85 ± 3.98%), which did not correlate with either CD45−CD34−CD146+/CD45−CD34−CD73+ subsets 
(Figure 2E,F). 
 
Figure 2. Detection of putative progenitor populations within the freshly isolated mononuclear cell 
fraction. Cell-surface marker panels were applied to identify putative progenitor populations. (A) 
Mononuclear cells were gated by forward scatter (FSC)–site scatter (SSC) profile. (B) Gating strategy 
for the detection of CD34−CD146+ cells in the CD45− cell fraction (orange). (C) Identification of cells 
co-expressing CD146 and NG-2 (red). (D) Gating strategy for the detection of CD34−CD73+ cells in 
the CD45− cell population (violet). (E–G) The relative abundance of specific progenitor sub-
populations were plotted against each other correlated by Spearman rank, tissue source of samples 
as indicated (fh = femoral head, ic = iliac crest, vb = vertebral body). n = 11 (E); n = 13 (F,G). 
2.3. Progenitor Abundance in the Freshly Isolated Mononuclear Cell Fraction Is Not Predictive of the 
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The abundance of progenitor populations within the MNC fraction from different bone marrow 
sources was assessed (Figure 3A–D). Inter-donor variability was apparent with no statistically 
significant difference in progenitor abundance, as determined by our marker panels, between 
Figure 2. Detection of putative progenitor populations within the freshly isolated mononuclear
cell fraction. Cell-surface marker panels were applied to identify putative progenitor populations.
(A) Mononuclear cells were gated by forward scatter (FSC)–site scatter (SSC) profile. (B) Gating strategy
for the detection of CD34−CD146+ cells in the CD45− cell fraction (orange). (C) Identification of cells
co-expressing CD146 and NG-2 (red). (D) Gating strategy for the detection of CD34−CD73+ cells in the
CD45− cell population (violet). (E–G) The relative abundance of specific progenitor sub-populations
were plotted against each other correlated by Spearman rank, tissue source of samples as indicated
(fh = femoral head, ic = iliac crest, vb = vertebral body). n = 11 (E); n = 13 (F,G).
2.3. ce i the Freshly Isolated Mononuclear Cell Fraction Is Not Predictive of the Derived
Monolayer Exp nded BMSC Population
f r e itor populations within the MNC fraction from diff rent bone marrow
sources was asse sed (Figure 3A–D). Inter-donor variability was apparent with no statistically significant
d fference in prog itor abunda ce, as determin d by our mark r panels, between different anatomical
sites. We next investigated whether MNC fractions containing a higher frequency of putative progenitor
populations would give rise to higher BMSC yields following monolayer expansion. The abundance of
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CD45−CD34−CD146+, CD146+/NG2+, or CD45−CD34−CD73+ populations in the freshly isolated
MNC fraction did not correlate with the yield of BMSCs at p0 (Figure 3E–G). No significant correlations
were apparent between the frequency of progenitors in the freshly isolated MNC fraction and the
population doubling time of the subsequently derived stromal population in the analyzed samples,
which were mainly derived from vertebral body (Figure 3I–K). We observed a trend between the
abundance of CD146+NG2+ cells and the population doubling time; however, this was not statistically
significant (p = 0.09, Figure 3J). We further analyzed CD45 (marker of the haematopoietic lineage) to
test whether the abundance of haematopoietic cells in the initial MNC population might affect the
growth kinetics of BMSCs. We found a trend of a negative correlation of the abundance of CD45+
leukocytes in the MNC fraction with the BMSC yield in p0, which was also not statistically significant
(p = 0.10, Figure 3H). No correlation was observed between the abundance of CD45+ in the MNC
fraction and the population doubling time (Figure 3L).
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correlated by Spearman rank to the total yield of cells derived as a proportion of the initial number of 
MNCs originally seeded. (I–L) The abundance of BMSC populations was further correlated by 
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2.4. Immunophenotyping of BMSCs 
BMSC lines adopted a classical cell-surface marker profile following selection and expansion on 
tissue culture plastic, as shown by positive expression for CD44, CD90, CD73, and CD105 (Table 2). 
Whilst CD146 was robustly expressed on cells derived from the iliac crest (ic) and the vertebral body 
Figure 3. Abundance of putative progenitor populations from different bone marrow sources
and correlation analyses. Comparison of the frequency of MSC populations, identified as
(A) CD45−CD34−CD146+ (n = 12), (B) CD146+NG2+ (n = 13), or (C) CD45−CD34−CD73+ (n = 17) and
(D) CD45+ leukocytes (n = 17) in bone marrow (BM)-derived MNCs from different sources. Frequency of
all cell populations was variable in individual donors but not significantly different in-between tissue
sources (fh = femoral head, ic = iliac crest, vb = vertebral body), as assessed by Kruskal–Wallis statistics
with Dunn’s multiple comparison test. (E–H) The relative abundance of BMSC populations was correlated
by Spearman rank to the total yield of cells derived as a proportion of the initial number of MNCs originally
seeded. (I–L) The abundance of BMSC populations was further correlated by Spearman rank to the
proliferation potential of the cells upon monolayer expansion, as shown by PDT.
2.4. Immunophenotyping of BMSCs
BMSC lines adopted a classical cell-surface marker profile following selection and expansion on
tissue culture plastic, as shown by positive expression fo CD44, CD90, CD73, a d CD105 (Table 2).
Whilst CD146 was robu tly expressed on c lls derived fr m the iliac crest (ic) and the vertebr l body
(vb), expression levels were more variabl at p0 an p1 in MSCs f om the femoral head (fh) (fh:
66.43 ± 22.69%, ic: 97.38 ± 2.39%, vb: 95.07 ± 2.92% CD146+ positive cells in p1, Table 2). NG2 was
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detected at variable levels in culture expanded MSC populations from across tissue sources, which was
also reflected in the variable abundance of CD146+/NG2+ double positive cells.
Table 2. Expression of pericyte markers CD146 and NG-2 and MSC markers CD44, CD73, CD90,
and CD105 in p0 and p1 BMSCs from different bone marrow sources was assessed by antibody staining
and flow cytometry (given as % of positively stained cells).
CD146 NG2 CD146/NG2 CD44 CD90 CD105 CD73 CD44/CD90CD105/CD73
P0 fh 87.5 ± 11.9 86.0 ± 17.8 75.1 ± 19.1 100 ± 0.0 94.5 ± 3.6 100 ± 0.1 100 ± 0.0 94.5 ± 3.6
ic 98.4 ± 1.3 88.7 ± 9.0 87.3 ± 9.1 100 ± 0.1 96.9 ± 1.1 99.90 ± 0.0 99.9 ± 0.1 96.9 ± 1.1
vb 97.7 ± 1.0 65.7 ± 18.5 64.3 ± 17.8 100 ± 0.0 93.7 ± 4.8 99.98 ± 0.0 100 ± 0.0 93.7 ± 4.8
P1 fh 66.4 ± 22.7 74.7 ± 16.6 47.0 ± 9.5 100 ± 0.0 97.2 ± 1.5 99. 8 ± 0.3 100 ± 0.0 97.1 ± 1.7
ic 97.4 ± 2.4 87.6 ± 13.0 85.2 ± 12.0 100 ± 0.1 96.6 ± 0.5 99.6 ± 0.5 99.7 ± 0.5 96.6 ± 0.4
vb 95.1 ± 2.9 73.8 ± 13.6 72.7 ± 13.4 100 ± 0.1 93.7 ± 4.8 99.9 ± 0.3 100 ± 0.0 97.8 ± 2.2
Data are means ± standard deviation. fh: femoral head, ic: iliac crest, vb: vertebral body.
2.5. Tri-Lineage In Vitro Differentiation
In vitro tri-lineage differentiation potential was tested for at least three BMSC donors from each
anatomical site. BMSCs from all anatomical sites readily mineralized, as shown by Alizarin Red S (ARS)
staining of monolayer cultures after three-week induction with osteogenic medium (Figure 4A–C).
Image quantification revealed no significant differences in the area of positive ARS staining between
the analyzed donors, although iliac crest derived BMSCs appeared to mineralize more readily and
reproducibly compared to femoral head and vertebral body derived cells (Figure 4D).
All BMSC sources formed physically stable chondrogenic pellets. Pellet size varied between donors
of all three bone marrow tissue sources (Table 3). Overall, BMSC donors analyzed here derived from iliac
crest (Figure 5B,C) and vertebral body (Figure 5E,F) formed larger pellets compared to femoral head
(Figure 5A). Representative images showing the full range of histological and immunohistochemical
staining (i.e., the least and the most responsive chondrogenic pellets) are shown in Figure 5, Figure 6,
and Figure 7. The sulphated glycosaminoglycan (sGAG) content of the extracellular matrix varied
between donors, as shown by Safranin-O staining, indicating a pattern of responders and non-responders
to TGFbeta-1 induced chondrogenesis (Figure 5, Table 3). In donors responsive to chondrogenic induction,
sGAG content appeared higher overall in cultures derived from iliac crest and vertebral body compared to
femoral head. Both type II (Figure 6) and type X collagen (Figure 7) were detected immunohistochemically
in all donors. In accordance with sGAG content, responding chondrogenic donors exhibited greater
immunostaining for collagens II and X compared to the poor chondrogenic cells.
All BMSC sources readily differentiated toward the adipogenic lineage, as indicated by
accumulation of lipid droplets staining positive for OilRed O (Figure 8).
Table 3. Chondrogenic differentiation of bone marrow stromal cells assessed using a semi-quantitative
histological score.
Chondrogenic Differentiation of Bone Marrow Stromal Cells
Source Age Sex Size Safranin-O Staining Score
Iliac crest 23 Female +++ +++ 6
Iliac crest 53 Male +++ + 4
Iliac crest 45 Female ++ + 3
Femoral head 83 Male ++ + 3
Femoral head 75 Female ++ + 3
Femoral head 51 Male + ++ 3
Vertebral body 77 Male ++ + 3
Vertebral body 60 Male ++ +++ 5
Vertebral body 48 Male +++ +++ 6
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stati tics with Dunn’ multiple comparison test. Scale bars 400 µm. n = 10.
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compared to femoral head (Figure 5A). Representative images showing the full range of histological 
and immunohistochemical staining (i.e., the least and the most responsive chondrogenic pellets) are 
shown in Figures 5, 6, and 7. The sulphated glycosaminoglycan (sGAG) content of the extracellular 
matrix varied between donors, as shown by Safranin-O staining, indicating a pattern of responders 
and non-responders to TGFbeta-1 induced chondrogenesis (Figure 5, Table 3). In donors responsive 
to chondrogenic induction, sGAG content appeared higher overall in cultures derived from iliac crest 
and vertebral body compared to femoral head. Both type II (Figure 6) and type X collagen (Figure 7) 
were detected immunohistochemically in all donors. In accordance with sGAG content, responding 
chondrogenic donors exhibited greater immunostaining for collagens II and X compared to the poor 
chondrogenic cells. 
All BMSC sources readily differentiated toward the adipogenic lineage, as indicated by 
accumulation of lipid droplets staining positive for OilRed O (Figure 8). 
 
Figure 5. Histological analysis of chondrogenically differentiated BMSCs. Safranin-O Fast Green 
Haematoxylin staining depicting sulphated-glycosaminoglycan content of chondrogenic pellet 
cultures. Representative images are presented from the least (A,C,E) and the most (B,D,F) responsive 
Figure 5. Histological analysis of chondrogenically differentiated BMSCs. Safranin-O Fast Green
Haematoxylin staining depicting sulphated-glycosaminoglycan content of chondrogenic pellet cultures.
Representative images are presented from the least (A,C,E) and the most (B,D,F) responsive
chondrogenic BMSC donors derived from (A,B) femoral head, (C,D) iliac crest, and (E,F) vertebral
body bone marrow. Scale bars 200 µm. n = 9.
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body bone marrow. Scale bars 200 µm. n = 9. 
 
Figure 6. Immunohistochemical detection of collagen type II. Representative images of collagen type 
II immunostaining are presented from the least (A,D,G) and the most (B,E,H) responsive 
chondrogenic BMSC donors derived from (A–C) femoral head, (D–F) iliac crest, (G–I) vertebral body 
bone marrow. (C,F,I) Negative controls. Scale bars 400 µm. n = 9. 
Figure 6. I unohistoche ical detection of collagen type II. Representative images of collagen type II
immunostaining are presented from the least (A,D,G) and the most (B,E,H) responsive chondrogenic
BMSC donors derived from (A–C) femoral head, (D–F) iliac crest, (G–I) vertebral body bone marrow.
(C,F,I) Negative controls. Scale bars 400 µm. n = 9.
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Figure 7. Immunohistochemical detection of collagen type X. Representative images of collagen type 
X immunostaining are presented from the least (A,D,G) and the most (B,E,H) responsive 
chondrogenic BMSC donors derived from (A–C) femoral head, (D–F) iliac crest, (G–I) vertebral body 
bone marrow. (C,F,I) Negative controls. Scale bars 400 µm. n = 9. 
Figure 7. I unohistoche ical detection of collagen type X. Representative images of collagen type X
immunostaining are presented from the least (A,D,G) and the most (B,E,H) responsive chondrogenic
BMSC donors derive from (A–C) femoral head, (D–F) iliac crest, (G–I) vertebral body bone marrow.
(C,F,I) Negative controls. Scal bars 400 µm. n = 9.
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Figure 8. Adipogenic differentiation of BMSCs from different bone marrow sources. Representative 
images of adipogenically differentiated BMSCs from different bone marrow sources (A) femoral head, 
(B) iliac crest, (C) vertebral body was assessed by Oil Red O staining of deposited lipid droplets. Scale 
bars 400 µm. n = 10. 
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3. Discussion
Inter-donor variability between BMSC cultures expanded in vitro poses major challenges not only
in terms of understanding their basic biology but also for the development of BMSC-based therapies.
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This is inherent of endogenous progenitor cell heterogeneity and the lack of selection criteria that are
functionally predictive. Moreover, progenitor populations remain insufficiently characterized with
regard to anatomical site, gender, and age. Here, we investigated whether abundance of progenitor
subsets found within the MNC fraction from bone marrow are phenotypically predictive for in vitro
derived stromal cell cultures, i.e., if the higher abundance of one specific subpopulation correlates with
better performance of the cell population derived from the MNC fraction. Therefore, we investigated
progenitor abundance in the fresh MNC fraction and performed donor matched evaluations of growth
kinetics and multi-lineage differentiation potential in vitro. In addition, we examined the influence of
tissue source, gender, and age on derived stromal cell populations.
We hypothesized that the abundance of discrete progenitor populations in the freshly isolated
MNC fraction may correlate with phenotypical variances in the derived stromal cells. For example, in
the event that a particular progenitor population is more responsive to TGFβ driven chondrogenesis
in vitro, should more of these cells be present in the original aspirate, it would be reasonable to
presume that derived plastic adherent BMSCs may differentiate superiorly compared to a culture
where fewer of these cells were originally present. To address this, we applied previously reported cell
surface marker panels to freshly isolated MNCs targeting putative progenitor subsets: CD146+NG2+,
CD45−CD34−CD146+, and CD45−CD34−CD73+.
Our data firstly revealed a large CD146+NG2+ population in comparison to less abundant
CD45−CD34−CD73+ and CD45−CD34−CD146+ subsets. Rather than denoting a perivascular
progenitor subset, it is likely that CD146+NG2+ cells comprise all pericytes, including the less abundant
CD45−CD34−CD146+ progenitor sub-population. CD146 and NG2 are reported as in situ markers of
the CD45−CD34−CD146+ perivascular cell population resident in adult tissues displaying plasticity
in vitro and following in vivo transplantation [20]. Although frequently cited as pericyte markers,
CD146 and NG2 are not specific to this cell type. CD146 (melanoma cell adhesion molecule) may be
expressed by several cell types in bone marrow, such as endothelial cells, pericytes, and vascular smooth
muscle cells [40]. NG2 (chondroitin sulphate proteoglycan 4) may be expressed by pericytes [41,42]
and on macrophages [43]. Expression of both CD146 and NG2 on pericytes is dynamic and may be
affected by the stage of angiogenesis, inflammation, and other external cues such as hypoxia [17,44,45].
Whilst endothelial cells may express CD146, they do not express NG2; therefore the likelihood of
endothelial cell detection in our panel was small. Nevertheless, we cannot rule out the possibility
that cell types other than pericytes were detected in the CD146+NG2+ panel. Secondly, we observed
a positive correlation between the frequency of CD45−CD34−CD146+ and CD45−CD34−CD73+
mononuclear cells, suggesting that both marker panels may identify the same subpopulation of cells.
Non-hematopoietic CD73+ cells are prevalent in bone marrow, and immunohistochemical studies
indicate they occupy stromal and endosteal but not perivascular locations [16]. CD146+ is additionally
expressed by reticular cells in the stromal compartment [16]. These studies together with our findings
support the existence of a dual CD146+CD73+ progenitor subset likely resident in the stromal niche
compartment of bone marrow.
As a field, we have yet to ascertain the developmental and the physiological basis for BMSC
heterogeneity in bone marrow. Many groups have characterized progenitor populations both vascular
and non-vascular associated in murine models and in man. If and how these populations are
related in terms of ancestral heritage and function remains unclear. In 2008, Crisan and colleagues
reported the in vitro multipotency of CD45-CD34-CD146+ cells sorted from multiple tissues including
bone marrow [20]. The authors described this population to be equivalent to that of perivascular
CD146+NG2+ cells or “pericytes”. Subsequent studies fueled the hypothesis that CD45−CD34−CD146+
cells may be bona fide progenitor cells in vivo and are the ancestor cells of all BMSCs [46]. Pericytes have
historically been described as mural support cells surrounding the endothelium functioning to regulate
capillary morphogenesis, stabilization, permeability, remodeling, and leukocyte trafficking [47,48].
Since it has not yet been demonstrated that all pericytes are progenitor cells, it appears that the
CD45−CD34−CD146+ surface marker panel is not sufficient to draw any conclusion on the origin
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and the function of the derived cell populations. Also, the hypothesis of a universal multipotent
MSC/pericyte cell population in virtually all vascularized tissues is challenged, since the multipotency
of these cells could not always be confirmed in vivo [21,49]. Moreover, recent developmental lineage
tracing and fate mapping studies in the mouse suggest that pericytes are heterogeneous in origin [50]
and do not give rise to tissue specific progeny in the organs in which they reside [51].
These and other studies challenge the theory that BMSCs share a common ancestral source and rather
suggest the existence of genetically and phenotypically distinct progenitor populations in adult bone
marrow, a notion that was recently proposed as a concept of a “paralogous stem-cell niche” model [52].
A greater understanding of the biological nature and the function of these discrete progenitors is
of paramount importance as we move forward to develop regenerative strategies for bone and articular
cartilage, utilizing these progenitor cell populations or, in most cases, a mixture thereof. A deep
knowledge of the regenerative potential of distinct cell population accompanied with straightforward
isolation strategies will facilitate the success of these therapies.
A principle finding of our study was that, in terms of abundance, none of the putative progenitor
cell subsets we detected by flow cytometry were predictive for the colony forming capacity or the
proliferation ability of derived BMSC populations. Of the heterogeneous BMSC populations present in
bone marrow, we know very little about which sub-populations are selected during plastic adhesion
and monolayer expansion. Determining this is complicated by the fact that, once removed from their
endogenous niche environment, BMSCs may alter cell-surface marker expression [9–12]. It may be
that phenotypic drift during monolayer expansion overshadows any potential functional differences
between progenitor subsets that may otherwise be predictive. Thus, it appears that, whilst cell
surface markers can be useful in characterizing stromal progenitors endogenously, they are less useful
for predicting the performance and indeed characterizing the in vitro derived culture. Improved
characterization of non-hematopoietic progenitor populations in bone marrow may identify novel,
more robust markers that can be used to select BMSCs on the basis of function. An alternative approach
is to avoid monolayer expansion altogether. In vitro expansion on tissue culture plastic induces
changes in BMSC morphology, gene and protein expression (including cell surface markers), growth
kinetics, and plasticity [26,53–59]. Thus, in vitro derived BMSC cultures are neither genetically nor
phenotypically representative of their in vivo counterparts [36]. The extent of phenotypic drift together
with the clinical and the economic disadvantages to in vitro culture has prompted research aiming
towards (i) intra-operative therapies using freshly isolated marrow cells and (ii) targeted approaches
to initiate MSC homing from the bone marrow to sites of injury. There is therefore a need to better
characterize freshly isolated bone marrow cell populations and discover predictive markers of their
therapeutic efficacy in vivo. To this end, three-dimensional (3D) co-culture systems surpassing tissue
culture plastic have been reported to maintain heterogeneity and cellular quiescence, allowing the
study of bone marrow cells in a micro-environment more akin to that in vivo [38,60–62].
In the donors analyzed in this study, we did not observe significant effects of patient age or
gender in terms of yield, growth kinetics, or multipotency of derived BMSC populations. At this
point, we cannot exclude that this is attributed to a bias induced to the relatively small number of
samples included in this study, presenting a major limitation of this work. The two best performing
chondrogenic donors in our study were isolated from the iliac crest marrow of a female patient aged
23 and the vertebral body marrow of a male patient aged 61. Contrary findings may be found in the
literature with some groups reporting differences in lifespan and/or growth kinetics between young
and older patients [24–30]. A sex dimorphism has been reported in murine MSCs [63] and in man [30],
although this area has yet to be fully investigated at the molecular level. As in many comparative BMSC
studies, such conflicting findings may be attributed to sample size limitations together with differences
in isolation/culture methods and outcome measurements. As in the majority of the aforementioned
studies, our data were limited in that gender and age groups were disproportionately represented
(10 female, 23 male; 10 < 50 yrs, 23 > 50 yrs).
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Previous studies comparing different bone marrow sources have indicated higher CFU forming
efficiency of cells isolated from vertebral body vs. iliac crest [33] but comparable multipotent
differentiation potential [34]. Our data revealed no significant difference between anatomical sites
in terms of BMSC yield normalized to total MNC fraction or the growth kinetics of derived stromal
cell populations. In terms of absolute numbers, however, MNC number and MSC yields at p0 were
consistently lower from the femoral head compared to the iliac crest and the vertebral body, which is
in accordance with other studies [35]. We observed that donor variation between MSC derived from
femoral head bone marrow was more prominent in terms of the relative abundance of progenitor cell
subsets detected in the freshly isolated MNC fraction. This was reflected following culture expansion,
where the percentage of CD146+ cells was also more variable when compared to vertebral body and
iliac crest. Furthermore, among the samples analyzed in this study, MSC populations derived from
femoral head marrow were overall inferior with respect to in vitro chondrogenesis compared to those
derived from the iliac crest and the vertebral body. Specifically, pellet size and the level of sGAG
and collagen protein staining appeared lower in responding chondrogenic donors from the femoral
head. In the number of analyzed donors, our flow cytometry data did not show differences in terms
of progenitor sub-population abundance when comparing femoral head to iliac crest and vertebral
body. Thus, it appears that, independent of the abundance of these progenitor populations in the
original tissue sample, femoral head derived stromal populations are more unpredictable and overall
inferior when chondrogenically differentiated in vitro compared to vertebral body and iliac crest.
Whilst this will have to be confirmed in future studies involving larger donor numbers, there could be
several explanations for this. A greater proportion of femoral head derived progenitors may be more
naive and/or not as responsive to TGFβ driven chondrogenesis. This could be investigated further by
assessing stemness genes and the expression/activity of TGFβ family members. Alternatively, there
may be a greater proportion of femoral head-derived progenitors that are lineage restricted. In addition,
the variability in femoral head-derived cell populations might be attributable in part from variations in
the microenvironment in which they reside, e.g., degenerated femoral head of patients undergoing hip
replacement surgery due to multiple reasons ranging from fractures or femoral necrosis to primary or
secondary coxarthrosis. In contrast, it can be hypothesized that the local microenvironment of BMSCs
from other tissue sources investigated in this study might be less affected by the disease state of the
individual donor.
In terms of clinical relevance, our findings suggest that the progenitor pool in the femoral head may
not effectively support chondrogenesis in vivo. Indeed, femoral head marrow stimulation techniques
aiming to recruit progenitors to the defect site result in variable, often unsatisfactory repair tissue that
fails long term and is associated with poorer clinical outcomes compared to autologous chondrocyte
implantation [64–67].
4. Materials and Methods
4.1. Bone Marrow Processing and Cell Isolation
Vertebral body, iliac crest, and femoral head bone marrow aspirates from patients undergoing
spinal surgery/arthroplasty were acquired with informed consent and full ethical approval (KEK Bern
2016-00414 (12 April 2016), KEK-ZH-NR:2014-0420 (10 November 2014), EK Regensburg 12-101-0127
(12 June 2012). Bone marrow aspirates were processed from a total of 33 patients. This included 10
female and 23 male donors with an age range of 14–91; femoral head donors were aged 74 ± 13 years,
iliac crest donors 43 ± 21 years, and vertebral body donors 63 ± 16 years (Table 1). Mononuclear
cells (MNCs) were isolated from bone marrow by density centrifugation using Histopaque-1077™
(Sigma-Aldrich, Buchs, Switzerland) as described before [22,38,47]. Specifically, bone marrow diluted
1:4 in phosphate buffered saline (PBS) was layered onto Histopaque®-1077 centrifuged at 800× g for
20 min without braking. The resultant buffy coat containing the MNC fraction was aspirated using
a Pasteur pipette and washed by two sequential centrifugations at 400× g for 15 min in cell culture
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media—alpha-MEM, 0.05% penicillin, and streptomycin (both GIBCO, Thermo Fisher Scientific, Zug,
Switzerland) 10% foetal calf serum (FCS, Seraplus, Pan-Biotech, Aidenbach, Germany, P30-3700).
A gated cell count was performed using a cell Scepter™ 2.0 Automated Cell Counter (Merck Millipore,
Schaffhausen, Switzerland) to determine cell number > 8 µm (to gate out red blood cells and cell debris).
MNCs were seeded at a density of 50,000 cells/cm2 into tissue culture flasks in cell culture media with
the addition of fibroblast growth factor-2 at 5 ng/mL (Fitzgerald, Co. Wicklow, Ireland). FGF2 is a
potent mitogen of BMSCs and is routinely used for monolayer expansion to maintain multipotency.
Four days later, non-adherent hematopoietic cells were removed. Cells were passaged when colonies
reached 80% confluency. The obtained cell count upon first passaging was recorded as an approximate
measure of MSC frequency in MNCs. MSCs were expanded in monolayer (3 × 103 cells/cm2) at 37 ◦C
and 5% CO2 and received media changes three times a week. At each passage, population doublings
were calculated using the following formula: LOG10 (final cell number/initial cell number)) × 3.33.
MSCs were cultured until passage 2 (p2) and then transferred to liquid nitrogen for long term storage
in cryopreservation media (FCS containing 8% DMSO (Sigma-Aldrich)).
4.2. Flow Cytometry Analysis
Flow cytometry analysis for hematopoietic and non-hematopoietic cell surface markers was
performed on freshly isolated mononuclear cells and on adherent cell populations at p0 and p1. Cells
were incubated with single or combinations of the following mouse monoclonal anti-human antibodies
in PBS containing 1% fetal calf serum for 30 min at 4 ◦C: CD45-Alexa 488 (1:20, Beckman Coulter, Nyon,
Switzerland), CD45-APC (1:5), CD73-PE-Cy7 (1:40), CD105-PE (1:40), CD90-BV421 (1:13), CD146-PeCy7
(1:20), HLA-DR-PE (1:5), CD19-PE (1:5), CD11b-PE (1:5, all BD Bioscience), CD44-APC (1:10), CD34-PE
(1:10, both Miltenyi Biotec, Bergisch-Gladbach, Germany), NG2-PE (1:10), PDGF-rβ-Alexa 700 (1:20,
both R&D Systems). Unstained isotype (IgG1-PeCy7 (1:20, BD Bioscience)) and single antibody controls
were included. Flow cytometry was performed using a BD Aria III, and a minimum of 25,000 events
were acquired for each sample, and data were analyzed using BD FACS Diva 6.1.3. Appropriate
compensation settings and gating were applied in order to account for cellular debris, cell doublets,
spectral overlap, and autofluorescence.
4.3. In Vitro Differentiation Assays
In vitro differentiation assays were performed using p2 BMSCs that were previously cryopreserved
in liquid nitrogen.
4.3.1. Chondrogenic Differentiation
For chondrogenic differentiation, 2.5 × 105 MSCs were centrifuged at 500× g in 1.5 mL eppendorf
tubes in chondrogenic induction media (DMEM high glucose medium, 0.11g/L sodium pyruvate (Sigma),
50 µg/mL ascorbic acid-2 phosphate (Sigma), 1% Insulin-Transferrin-Selenium + Premix (Corning, New
York, NY, USA), 100 nM Dexamethasone (Sigma) and 10 ng/mL TGF-β-1 (Fitzgerald)). Culture media was
replaced after 3 days and three times a week thereafter for a total of 21 days. Chondrogenic pellets were
fixed in 70% methanol and snap-frozen, and cryosections were taken at 10 µm. Cryosections were stained
with 0.1% Safranin-O and 0.02% Fast Green for detection of sulphated glycosaminoglycans (sGAG) or
used for immunohistochemistry. Chondrogenic differentiation was assessed using a semi-quantitative
score according to pellet size and the degree of Safranin-O staining (Table 3).
All steps during immunohistochemistry were performed at room temperature (RT) unless
otherwise stated. Cryosections were blocked for 30 min in 0.3% hydrogen peroxide in methanol before
treatment with 1 U/mL hyaluronidase (Sigma-Aldrich, cat: H3506) in phosphate buffered saline +
1% Tween (PBS-T) for 1 h at 37 ◦C. Sections were blocked with horse serum (Vector Laboratories,
Burlingame, CA, USA, cat: S-2000) and diluted 1:20 in PBS-T for 1 h before incubation with (i) 5 µg/mL
mouse monoclonal anti-collagen X (Affymetrix eBioscience, Thermo Fisher Scientific, cat: 14-9771) or
(ii) mouse monoclonal anti-collagen II (DSHB, CIICI) diluted 1:20 in PBS-T. Secondary detection was
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performed using the Vectastain Elite ABC kit according to the manufacturer’s instructions (Vector
Laboratories cat: PK-6100). Briefly, cryosections were washed, and biotinylated anti-mouse IgG
secondary antibody was applied at 1:200 in PBS-T for 30 min (Vector Laboratories cat: BA-2001).
After washing, sections were incubated with ABC complex for 30 min. Following another series of
wash steps, ImmPACT DAB was applied for 4 min in the dark (Vector Laboratories, cat: SK-4105) prior
to counterstaining with Mayer’s Haematoxylin (Fluka). Sections were dehydrated through a series of
graded alcohols, cleared with xylene, and mounted with Eukitt mounting medium (Sigma). Sections
were visualized and imaged using a Zeiss Axioplan 2 microscope (Oberkochen, Germany). Of note,
the specificities of type II and type X antibodies were validated by testing on human articular cartilage
and human scoliotic endplate, respectively (not shown).
4.3.2. Osteogenic Differentiation
For osteogenic differentiation, cells were seeded in triplicates at a density of 20,000 cells/cm2
on thermanox coverslips (Thermo Fisher Scientific) in 24-well tissue culture plates and were either
incubated in control medium (DMEM 1 g/L glucose, 10% FBS (Seraplus, Pan)) or osteogenic differentiation
medium (DMEM 1 g/L glucose, 10% FBS, 50 µg/mL ascorbic acid, 5 mM glycerol-2-phosphate, 10 nM
dexamethasone (all substances purchased from Sigma-Aldrich)). Cells were cultured for 21 days with
three media changes per week. Mineral deposition was examined by alizarin red staining. For the
staining, wells were washed twice with PBS, and cells were fixed for 15 min with 4% formaldehyde.
After three washes with demineralized water, cells were stained with a 40 mM alizarin red S solution
(Sigma-Aldrich) for 60 min. Excess stain was removed by repeated washing with demineralized water,
and staining was visualized using an Axiovert40 CFL microscope (Zeiss). To compare osteogenic
differentiation efficiency in-between different donors, stained wells were scanned using an EVOS® FL
Auto Cell Imaging System (Thermo Fisher Scientific), and the percentage of stained area was calculated
in ImageJ (Rasband, NIH, Bethesda, MD, USA) by manually selecting cell-covered areas, transforming
the image to grey values, and using an individual threshold to select for positively stained regions.
4.3.3. Adipogenic Induction
For adipogenic differentiation, cells were seeded in triplicates at a density of 16,000 cells/cm2 in
24-well plates and incubated either in control medium (DMEM 4.5 g/L glucose, 10% FBS) or adipogenic
differentiation medium (DMEM 4.5 g/L glucose, 10% FBS (Seraplus, Pan), 5 µg/mL insulin, 1 µM
dexamethasone, 0.5 mM isobutylmethylxanthine, 60 µM indomethacine). Media were changed 3 times
per week. After 2 weeks, wells were washed, fixed, and stained with oil red O solution (Sigma-Aldrich)
to visualize lipid droplets. Stained plates were observed using an Axiovert40 CFL microscope.
4.4. Statistics
Data are presented from individual donors. Error bars indicate the standard deviation. Flow
cytometry data are presented as means +/− standard deviations. Kruskal–Wallis analysis with Dunn’s
multiple comparison test and Spearman rank correlation analysis was performed where appropriate
using Prism software (GraphPad Software, La Jolla, CA, USA).
5. Conclusions
This study illustrates once more the large heterogeneity of bone marrow derived BMSC populations,
which needs to be considered when making conclusions on the regenerative potential of these cells.
Moreover, based on the donors included in the investigation, it appears that BMSCs derived from
the femoral head were less abundant and performed inferiorly in terms of growth kinetics and
chondrogenic differentiation compared to equivalent populations from the vertebral body and the
iliac crest bone marrow. Since only a limited number of donors were assessed in these experiments,
this needs to be confirmed in future studies. Contrary to our hypothesis, the presence of discrete
progenitor cell subsets within the mononuclear cell fraction as identified by cell-surface marking
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profiling was not phenotypically predictive for derived BMSC cultures expanded in the monolayer.
Demographically, neither gender nor age appeared to significantly influence the abundance or the
multi-lineage differentiation potential of derived BMSCs. Considering our findings and those of others,
although more clonogenic progenitor populations may be more readily derived from the marrow of
younger patients, it is clear that the bone marrow of older individuals does indeed retain endogenous
progenitors capable of multipotent differentiation in vitro and therefore represents an important adult
stem cell pool for regenerative therapies. Greater characterization of resident tissue progenitors,
for example, whole genome sequencing, micro-RNA, and epigenetic analysis, may help us better
understand BMSC heterogeneity and the endogenous roles of these stromal progenitors in adult bone
marrow. Furthermore, the development of 3D culture systems that better recapitulate the bone marrow
microenvironment may negate the phenotypic drift experienced by BMSCs on tissue culture plastics,
thus allowing us to better study naive BMSC biology. Ultimately, this knowledge will allow us to
fine-tune BMSC behavior and develop more successful regenerative therapies for clinical practice.
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Abbreviations
ARS alizarin red S
BMSC bone marrow stromal cell
CD cluster of differentiation
CFU colony forming unit
DMSO dimethyl sulfoxide
FCS foetal calf serum
FH femoral head
IC iliac crest
LepR leptin receptor
MEM minimum essential medium
MNC mononuclear cell
MSC mesenchymal stem cell or mesenchymal stromal cell
PBS phosphate buffered saline
PDGF platelet-derived growth factor
PDT population doubling time
RT room temperature
sGAG sulphated glycosaminoglycans
TGF transforming growth factor
VB vertebral body
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